Clinuvel: Afamelanotide (SCENESSE): Phase 3, Pfizer: Ritlecitinib (LITFULO): Phase 3, AbbVie: Upadacitinib (RINVOQ): Phase 3, Incyte: Ruxolitinib (OPZELURA): Approved, Amgen: Ordesekimab (AMG 714): Discontinued, Vyne Therapeutics: Repibresib (VYN-201): Discontinued, Dermavant: Tapinarof cream (VTAMA): Inactive, Pfizer: Brepocitinib: Phase 2, Edesa Biotech: EB06: Phase 2, Sun Pharmaceutical: AS012: Phase 2, Jiangsu HengRui Medicine: VC005: Phase 2, Forte Biosciences: FB102: Phase 1b, Teva Pharmaceutical: TEV-408: Phase 2b, Dren Bio: Dibotatug (DR-01): Phase 1
Clinuvel: Afamelanotide (SCENESSE): Phase 3, Pfizer: Ritlecitinib (LITFULO): Phase 3, AbbVie: Upadacitinib (RINVOQ): Phase 3, Incyte: Ruxolitinib (OPZELURA): Approved, Amgen: Ordesekimab (AMG 714): Discontinued, Vyne Therapeutics: Repibresib (VYN-201): Discontinued, Dermavant: Tapinarof cream (VTAMA): Inactive, Pfizer: Brepocitinib: Phase 2, Edesa Biotech: EB06: Phase 2, Sun Pharmaceutical: AS012: Phase 2, Jiangsu HengRui Medicine: VC005: Phase 2, Forte Biosciences: FB102: Phase 1b, Teva Pharmaceutical: TEV-408: Phase 2b, Dren Bio: Dibotatug (DR-01): Phase 1
//The Vitiligo News
Bringing the latest news from all areas of the vitiligo space.
//The Vitiligo State of Mind
Will you answer the call to help make a massive contribution to vitiligo investigation?
Want to talk to us about your vitiligo situation?
//The Vitiligo Thoughts
